Skip to content

Locomotion after stroke

Locomotion after stroke - LokS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00026799
Enrollment
90
Registered
2022-05-09
Start date
2022-05-10
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I63.9

Interventions

Group 1: In stroke patients with impaired leg motor function the following parameters are tested: electrophysiological parameters such as MEP/RMT and online-rTMS-interference above ipsilesionel and co

Sponsors

Uniklinik Köln
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 95 Years

Inclusion criteria

Inclusion criteria: written consent, ischaemic stroke, hemiparesis with impaired unilateral leg-motor function

Exclusion criteria

Exclusion criteria: Subjects who are legally detained in an official institute (§20 MPG), participation in a clinical trial within the last 12 weeks, electronic implants or ferromagnetic implants located in the head, neck or thorax (eg, clips, intracranial shunt, artificial heart valve, pacemaker), medication pump (eg, insulin pump), metal splinters in eye or head, pregnancy/breastfeeding, severe neurodegenerative disease, severe neuroinflammatory disease, history of seizures/epilepsy, physical addiction to alcohol, medication or drugs (excluded: nicotine), insufficient compliance, present or past malignant tumour involving the central nervous system, severe psychiatric disease, clinically manifest bilateral hemiparesis or infarcts in the primary motor cortex or along the corticospinal tract in the hemisphere ipsilateral to the hemiparesis, pre-existing cerebral infarctions with hemiparesis or pre-existing cerebral infarctions in the primary motor cortex or along the corticospinal tract, excluding microvascular changes (eg, clinically asymptomatic lacunae 20, blood glucose imbalances resistant to treatment (300 mg/dL), elevated blood pressure resistant to treatment (>185/110 mm Hg), systemic thrombolysis using alteplase or thrombectomy within the last 24 hours before enrolment in study, medication with benzodiazepines, high-potency antipsychotics or tricyclic antidepressants before hospitalisation or long-term during hospitalisation.

Design outcomes

Primary

MeasureTime frame
neuronavigated TMS: M1 (M. tibialis anterior and M. interosseus dorsalis manus) ipsilesionel and contralesionel: alterations in RMT und MEP response patterns in acute and chronic stroke patients. Online-rTMS-Intereference: changes in finger and feet tapping parameters after stimulation of M1 foot and hand representation ipsilesional and contralesional Additional comparison to/between (young and elderly) healthy control subjects.

Secondary

MeasureTime frame
Correlation of the extend of electrophysiological alterations and leg function in stroke patients and in healthy control subjects. Additionally, longitudinal observations in chronic stroke patients. Stance- and Gait-analysis: Romberg standing test Chair Rising Test Repetition Test Heel Rise Test Gait analysis: fast walking clinical scores: Handedness Questionnaire modified Rankin Scale (mRS) Rivermead Mobility Index NIH Stroke Scale (NIHSS) Fugl-Meyer Upper Extremity (FM-UE), Fugl-Meyer Lower Extremity (FM-LE) Short Physical Performance Battery Action Research Arm Test (ARAT) Vigorimeter grip-force , plantarflexion - force finger tapping speed, feet tapping speed Timed-Up-and-Go test (TUG) 10 m walk test MRT-imaging: structural imaging BOLD fMRT Resting-State-measurement BOLD fMRT during simple motoric task

Countries

Germany

Contacts

Public ContactVeronika Wunderle

Klinik für Neurologie, Uniklinik Köln

veronika.wunderle@uk-koeln.de04922147832052

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026